Patents by Inventor Tom Vasicek

Tom Vasicek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Molecular malignancy in melanocytic lesions
    Patent number: 9758829
    Abstract: Disclosed are methods for determining whether a melanocyte-containing sample (such as a nevus or other pigmented lesion) is benign or a primary melanoma. These methods can include detecting (at the molecular level, e.g., mRNA, miRNA, or protein) the expression of at least two disclosed genes in a biological sample obtained from a subject. Also provided are arrays and kits that can be used with the methods.
    Type: Grant
    Filed: June 24, 2013
    Date of Patent: September 12, 2017
    Assignees: HTG Molecular Diagnostics, Inc., John Wayne Cancer Institute
    Inventors: Hui Wang, Christopher Roberts, Krishna Maddula, Zhenquiang Lu, Tom Vasicek, B J Kerns, Bruce E. Seligmann, Dave S. B. Hoon
  • MOLECULAR MALIGNANCY IN MELANOCYTIC LESIONS
    Publication number: 20150176072
    Abstract: Disclosed are methods for determining whether a melanocyte-containing sample (such as a nevus or other pigmented lesion) is benign or a primary melanoma. These methods can include detecting (at the molecular level, e.g., mRNA, miRNA, or protein) the expression of at least two disclosed genes in a biological sample obtained from a subject. Also provided are arrays and kits that can be used with the methods.
    Type: Application
    Filed: June 24, 2013
    Publication date: June 25, 2015
    Applicants: HTG Molecular Diagnostics, INc., John Wayne Cancer Institute
    Inventors: Hui Wang, Christopher Roberts, Krishna Maddula, Zhenquiang Lu, Justin Brown, Tom Vasicek, BJ Kerns, Bruce E. Seligmann, Dave S.B. Hoon
  • Quantitative nuclease protection assay (QNPA) and sequencing (QNPS) improvements
    Patent number: 8741564
    Abstract: The present disclosure provides an improvement to quantitative Nuclease Protection Assay (qNPA) and quantitative Nuclease Protection Sequencing (qNPS) methods. The disclosed methods use nuclease protection probes (NPPs) that include 5?-end and/or 3-end flanking sequences, which provide a universal hybridization and/or amplification sequence. The disclosed methods can be used to sequence or detect target nucleic acid molecules, such as those present in fixed or insoluble samples.
    Type: Grant
    Filed: April 26, 2012
    Date of Patent: June 3, 2014
    Assignee: HTG Molecular Diagnostics, Inc.
    Inventors: Bruce Seligmann, Debrah Thompson, Tom Vasicek, Debra A. Gordon
  • QUANTITATIVE NUCLEASE PROTECTION ASSAY (QNPA) AND SEQUENCING (QNPS) IMPROVEMENTS
    Publication number: 20140087954
    Abstract: The present disclosure provides an improvement to quantitative Nuclease Protection Assay (qNPA) and quantitative Nuclease Protection Sequencing (qNPS) methods. The disclosed methods use nuclease protection probes (NPPs) that include 5?-end and/or 3-end flanking sequences, which provide a universal hybridization and/or amplification sequence. The disclosed methods can be used to sequence or detect target nucleic acid molecules, such as those present in fixed or insoluble samples.
    Type: Application
    Filed: April 26, 2012
    Publication date: March 27, 2014
    Applicant: HTG Molecular Diagnostics, Inc.
    Inventors: Bruce E. Seligmann, Debrah Thompson, Tom Vasicek, Debra A. Gordon